Bioptik Technology

Bioptik Technology EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Bioptik Technology (4161.TWO) as of Nov 2, 2026 is 6.05 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 7.86 % — a change of -23.07% (lower).

EBIT/Assets

6.05 %

YoY

-23.07%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Bioptik Technology is 2024 6.05 % . Operating Income to Assets Ratio (EBIT/Assets) of Bioptik Technology was 2023 7.86 % . It decreases by -23.07% lower compared to the previous year.

The Bioptik Technology EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2017
0.32 TWD
Jan 1, 2018
0.05 TWD
Jan 1, 2019
0.03 TWD
Jan 1, 2020
-4.01 TWD
Jan 1, 2021
1.78 TWD
Jan 1, 2022
4.74 TWD
Jan 1, 2023
7.86 TWD
Jan 1, 2024
6.05 TWD
The Bioptik Technology EBIT/Assets history
YEAREBIT/AssetsYoY
6.05 %-23.07%
7.86 %+65.98%
4.74 %+165.94%
1.78 %-144.44%
-4.01 %-13,441.89%
0.03 %-33.63%
0.05 %-85.69%
0.32 %-72.94%
1.17 %-69.68%
3.86 %+61.08%
2.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioptik Technology Stock analysis

What does Bioptik Technology do? Bioptik Technology, Inc. generates revenue through the sale of hyaluronic acid-based skincare products and medical diagnostic equipment. The company sells multifunctional blood sugar, cholesterol, uric acid, and heme detectors under the Easy Mate and Easy Touch brands, along with testing paper products for these parameters. Its cosmetic line, distributed under ACUREAL, includes toning lotions, essences, facial masks, and face cleaning products. Domestic and international markets are the primary sales channels for both product categories. The firm targets healthcare providers and consumers seeking at-home medical monitoring solutions through its Easy Mate and Easy Touch devices. ACUREAL skincare products appeal to customers interested in biological and medical cosmetics for daily skincare routines. Bioptik Technology focuses on the domestic market and overseas markets for product distribution, ensuring broad accessibility across different regions. Easy Mate and Easy Touch are the key medical equipment brands, while ACUREAL represents the cosmetic segment. The company's product portfolio combines medical diagnostics with skincare, serving two distinct consumer segments: health-conscious individuals monitoring vital metrics and users seeking specialized skincare solutions. This dual approach allows Bioptik Technology to leverage its research and development capabilities across both medical and cosmetic applications. Bioptik Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioptik Technology stock

Operating Income to Assets Ratio (EBIT/Assets) of Bioptik Technology is 6.05 % in 2024.

Operating Income to Assets Ratio (EBIT/Assets) of Bioptik Technology changed from 7.86 % to 6.05 %, representing a -23.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Bioptik Technology since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Bioptik Technology with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Bioptik Technology

All Key Metrics — Bioptik Technology